TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

In Segment A, contributors will get unique doses and schedules of oral ABBV-744 tablet to determine safe dosing program. More individuals will probably be enrolled in the discovered monotherapy dosign routine. In Phase B, members will receive oral ruxolitinib and ABBV-744 will be specified as "incorporate-on" therapy. In Phase C, individuals will a